Table 1—

Retrospective database studies of OHA for type 2 diabetic patients

ReferencePopulationMedicationsFollow-up (months)HbA1cAge (years)nAdherence ratePersistance (percent)Persistance (days)
Boccuzzi et al. (11)PBO, new startOHA monotherapy1260 ± 1479,49879%58%*83 ± 71
Brown et al. (12)HMO, new startOHA + Insulin(10 years)693 all70%
Catalan et al. (13)CanadaAcarbose1251 ± 9216 young16%*83
72 ± 5677 elderly20%*105
Chlechanowski et al. (14)HMO, allOHA + Insulin127.4 ± 1.464 ± 11119 not depressed93%
8.0 ± 1.5121 depressed85%
Dailey et al. (15)Medicaid, new startMonotherapy1837,43149%36%*
Polytherapy36%22%*
Dezii and Kawabata (16)PBOGlipizide, o.d.1255 ± 1399261%44%*
Glipizide, b.i.d.52%36%*
Donnan et al. (17)ScotlandMonotherapy12682,849(35% > 90%)300
Polytherapy(27% > 90%)
Evans et al. (18)ScotlandSulfonylurea6672,27587%
Melformin641,35083%
Mellkian et al. (19)PBOMonotherapy663 ± 1510554%
Mono to combination77%
Polytherapy65971%
PBOPoly to combination87%
Morningstar et al. (20)CanadaOHA363,35886%
Rajagopalan et al. (21)PBOOHA + Insulin2453195,400 all81%
28,001 new start81%
Scheclman et al. (22)ClinicOHA + Insulin158.1 ± 2.050 ± 1181080 ± 21%
Sclar et al. (23)MedicaidOHA1259 ± 1097539%
Spoelstra et al. (24)NetherlandOHA126341185 ± 15%
Venturini et al. (25)HMOSulfonylurea2459 ± 1178683 ± 22%
  • *

    * Persistance for 12 months;

  • persistance for 24 months

  • persistance for 6 months, §adherence rates excluding categorical data. HMO, health maintenance organization; PBO, pharmacy benefit organization.